NEW YORK-Despite considerable progress in the management and treatment of cancer in the overall population, cancer-related mortality among the elderly increased by 20% between 1970 and 1984. Cancer is often undertreated in the elderly, which affects their prognosis, said Roberto Bernabei, MD, of the Universita Cattolica del Sacro Cuore, Rome.
NEW YORKDespite considerable progress in the management and treatment of cancer in the overall population, cancer-related mortality among the elderly increased by 20% between 1970 and 1984. Cancer is often undertreated in the elderly, which affects their prognosis, said Roberto Bernabei, MD, of the Universita Cattolica del Sacro Cuore, Rome.
Dr. Bernabei, who spoke at the Fifth International Conference on Geriatric Oncology, believes a new approach is needed to "deal with the ‘peculiarities’ of the elderly cancer patient." At his institution, Dr. Bernabei and his colleagues have developed and use a comprehensive geriatric assessment tool.
The new instrument, Minimum Data Set for Cancer (MDS-CA), documents the patient’s oncologic screening and treatment data, and provides a structured, multidimensional assessment of the patient’s general health, including cognitive and functional parameters, emotional and behavioral patterns, nutritional status, co-morbidities, lifestyle and preventive measures, quality of life, pain status, activity and movement status, continence status, informal support availability, and overall medications. "Such a tool," Dr. Bernabei said, "will provide an assessment that can help us build treatment decisions and monitor the treatment."
They have used this new instrument on 220 consecutive elderly patients referred to the oncologic consultation team after a new diagnosis of cancer. "We wanted to define the functional characteristics of these patients and understand who was treated with chemotherapy/radiotherapy and why," he said. Dr. Bernabei stressed that this approach already has shown "considerable benefits in different settings and for conditions other than cancer."
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.